Novo Nordisk shares tumble as much as 10% after heart drug trial miss

The stock fell after the drugmaker said a late-stage study showed its heart treatment did not reduce major cardiovascular events versus placebo.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.